Expression of ERCC1, RRM1 and LRP in Non-small Cell Lung Cancers and their Influence on Chemotherapeutic Efficacy of Gemcitabine Concomitant with Nedaplatin

  • Qiu, Zhen-Qin (Unified Supply Center, The 89th Hospital of Chinese People's Liberation Army) ;
  • Zhao, Kun (Department of Oncology, The 89th Hospital of Chinese People's Liberation Army)
  • Published : 2014.09.15


Objective: To explore the clinical efficacy of gemcitabine concomitant with nedaplatin and drug resistance in the treatment of non-small cell lung cancer (NSCLC) and associated molecular predicators. Materials and Methods: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. Short-term and long-term efficacies, adverse responses as well as the expression of nucleotide excision repair cross complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and lung resistance-related protein (LRP) in NSCLC tissues in both groups were assessed. Results: The short-term objective response rate (ORR) and disease control rate (DCR) were 35.3% (12/34) and 76.5% (26/34) in the observation group and 38.2% (13/34) and 85.3% (29/34) in the control group, respectively, the differences not being statistically significant. The time to progression (TTP) in both groups were 1~12 months, while the median TTP was 135 d and 144 d, respectively. Though the survival was slightly higher in the control group, there were no significant differences in TTP and survival time. The rates of decreased hemoglobin, vomiting and nausea as well as renal toxicity were evidently lower in the observation group, while other adverse responses demonstrated no significant difference. The positive expression rates of ERCC1, RRM1 and LRP were 47.1% (16/34), 61.8% (21/34) and 64.7% (22/34) in the observation group, respectively. Compared with negative ERCC1 expression, ORR had decreasing trend and the overall survival time (OS) decreased significantly in patients with positive ERCC1 expression, which were markedly decreased by the positive expressions of RRM1 and LRP. Conclusions: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. Additionally, the positive expressions of ERCC1, RRM1 and LRP may increase patient drug resistance, so they can be applied as the chemotherapeutic predicators to guide individualized therapy of NSCLC patients.


  1. He YF, Ji CS, Hu B, et al (2013). A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol, 19, 5910.
  2. Jiang J, Liang X, Zhou X, et al (2012). ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep, 39, 6933-42.
  3. Kaya V, Yildirim M, Demirpence O, et al (2013). Prognostic significance of basic laboratory methods in non- small-celllung cancer. Asian Pac J Cancer Prev, 14, 5473-6.
  4. Lee JJ, Maeng CH, Baek SK, et al (2010). The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 70, 205-10.
  5. Mutlu H, Buyukcelik A, Aksahin A, et al (2013). Does sunlight exposure improve survival in patients with non-small cell lung cancer? Asian Pac J Cancer Prev, 14, 6301-4.
  6. Natukula K, Jamil K, Pingali UR, et al (2013). The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians. Asian Pac J Cancer Prev, 14, 5275-9.
  7. Oven Ustaalioglu BB, Unal OU, Turan N, et al (2013). Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences. Asian Pac J Cancer Prev, 14, 6287-92.
  8. Cai Y, Wang JY, Liu H (2013). Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev, 14, 5699-703.
  9. Dalla-Torre CA, de Toledo SRC, Yoshimoto M, et al (2007). Expression of major vault protein gene in osteosarcoma patients. J Orthop Res, 25, 958-63.
  10. Rossi D, Graziano F, Catalano V, et al (2001). A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study. Anticancer Res, 22, 3087-92.
  11. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  12. Sugiyama T, Hirose T, Nakashima M, et al (2011). Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer. Oncology, 81, 273-80.
  13. Teramoto K, Asada Y, Ozaki Y, et al (2012). A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol, 70, 531-7.
  14. Aydiner A, Ciftci R, Karabulut S, et al (2013). Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev, 14, 6109-14.
  15. Bepler G, Kusmartseva I, Sharma S, et al (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 24, 4731-7.
  16. Ueno H, Ioka T, Ikeda M, et al (2013). Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol, 31, 1640-8.
  17. Unal D, Eroglu C, Kurtul N, et al (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.
  18. Valle J, Wasan H, Palmer D H, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81.
  19. Wang X, Zhao J, Yang L, et al (2010). Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol, 27, 484-90.
  20. Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71.
  21. Wang M, Gu J, Wang HX, et al (2012). Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pac J Cancer Prev, 13, 4153-6.

Cited by

  1. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer vol.16, pp.10, 2015,
  2. Expression of Molecular Markers in Primary Sites and Metastatic Lymph Nodes of Lung Cancer Patients vol.23, pp.1643-3750, 2017,